Record stringlengths 1 197k |
|---|
* The inter-observer variation in diagnosing and sub-typing periocular BCC decreases with increasing experience in the scanning procedure. |
* The number of scans to correctly interpret D-OCT decreases with increasing experience in the scanning procedure. |
* Delineation of periocular BCC tumour extension is possible using both D-OCT probes conditions: BCC - Basal Cell Carcinoma conditions: BCC conditions: Skin Diseases conditions: Eyelid Tumor conditions: Eyelid Diseases studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 210 type: EST... |
<|newrecord|> nctId: NCT06279130 id: N23NEO briefTitle: Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations acronym: NEOASIS overallStatus: RECRUITING date: 2024-01-29 date: 2029-01-29 date: 2034-01-29 date: 2024-02-26 date: 2024-02-26 name: The Netherlands Cancer ... |
<|newrecord|> nctId: NCT06279117 id: 2023/9/8 briefTitle: The Effect of Therapeutic Touch on Exam Anxiety overallStatus: RECRUITING date: 2024-01-15 date: 2024-02-23 date: 2024-03-10 date: 2024-02-26 date: 2024-02-26 name: Dokuz Eylul University class: OTHER briefSummary: Aim: This study was planned to determine the ef... |
Method: Students who met the inclusion criteria were divided into therapeutic touch and control groups using the randomization method. After the groups were determined, the students filled out the Introductory Information Form and the State Exam Anxiety Scale. 30 minutes before the exam, therapeutic touch was applied t... |
<|newrecord|> nctId: NCT06279104 id: 2023-TJ-OCCC briefTitle: A Comparative Study of the Treatment of Real-world Patients With Clear Cell Carcinoma of the Ovary overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2025-05-01 date: 2025-05-01 date: 2024-02-26 date: 2024-02-26 name: Tongji Hospital class: OTHER name:... |
* What is the efficacy of physician's choice of chemotherapy in relapsed/refractory OCCC patients in the real world? |
* Is ICI-based therapy more effective than physician's choice of chemotherapy in real-world for relapsed/refractory OCCC patients? |
* Dose the combinational regimens of sintilimab plus bevacizumab in Sintilimab Plus Bevacizumab in Recurrent/Persistent Ovarian Clear Cell Carcinoma (INOVA) trial more effective than physician's choice of chemotherapy? |
Participants will be respectively retrieved and extracted de-identified, longitudinal electronic health records (EHR)-derived data. conditions: Ovarian Clear Cell Carcinoma studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: RETROSPECTIVE count: 150 type: ESTIMATED name: physician's choice of chemot... |
<|newrecord|> nctId: NCT06279091 id: A0104023PP briefTitle: Correlation of Children and Parental Anxiety and Effectiveness of Breathing Exercises on Anxiety Reduction overallStatus: ACTIVE_NOT_RECRUITING date: 2023-05-23 date: 2023-11-05 date: 2024-05-23 date: 2024-02-26 date: 2024-02-26 name: Mansoura University class... |
Control group (Group I). Diaphragmatic Breathing group (Group II). Bubble Blower Breathing group (Group III). primaryPurpose: OTHER masking: NONE count: 90 type: ESTIMATED name: Diaphragmatic Breathing name: Bubble Blower Breathing name: Tell Show Do measure: scale of dental anxiety by Corah Dental Anxiety Scale (CDAS)... |
<|newrecord|> nctId: NCT06279078 id: AJOUIRB-DB-2023-446 briefTitle: Long-term Effect of Steroid on Metabolic Diseases in Asthmatics overallStatus: RECRUITING date: 2023-12-30 date: 2024-12-30 date: 2025-06-30 date: 2024-02-26 date: 2024-02-26 name: Ajou University School of Medicine class: OTHER name: AstraZeneca brie... |
i. High cumulative dose of corticosteroid is related to the prevalence of osteoporosis/osteoporosis in the long-term management of adult asthma. |
ii. High cumulative dose of corticosteroid can affect populations that have a high-risk of osteoporosis (females over 50 years of age). |
iii. High cumulative dose of corticosteroid is related to the prevalence of diabetes mellitus, hypertension, and hyperlipidemia in the long-term management of adult asthma. |
iv. High cumulative dose of corticosteroid affects bone metabolism-related diagnostic tests and laboratory values and the prescription rate of bone metabolism-related medications. conditions: Asthma conditions: Osteoporosis, Osteopenia conditions: Osteoporosis Risk conditions: Osteoporotic Fractures studyType: OBSERVAT... |
<|newrecord|> nctId: NCT06279065 id: 373/23-EP briefTitle: Investigation of the Influence of the Human Microbiome on the Pathogenesis and Recurrence Probability in Giant Cell Arteritis acronym: GCA-Biom overallStatus: RECRUITING date: 2024-02-18 date: 2026-02-18 date: 2028-02 date: 2024-02-26 date: 2024-02-26 name: Uni... |
<|newrecord|> nctId: NCT06279052 id: RC31/23/0535 briefTitle: Adolescent Projections During Transition in Prader-Willi Syndrome acronym: APT-WILL overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2024-12-01 date: 2024-12-01 date: 2024-02-26 date: 2024-02-28 name: University Hospital, Toulouse class: OTHER briefS... |
<|newrecord|> nctId: NCT06279039 id: KY20230116-06 briefTitle: Clinical Observation of Exosomes in Patients After Q-switched Laser Surgery overallStatus: RECRUITING date: 2022-09-01 date: 2024-08-31 date: 2024-12-31 date: 2024-02-26 date: 2024-02-26 name: Nanjing First Hospital, Nanjing Medical University class: OTHER ... |
<|newrecord|> nctId: NCT06279026 id: PG-006-5 briefTitle: UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma overallStatus: RECRUITING date: 2024-04-01 date: 2027-04-01 date: 2027-07-01 date: 2024-02-26 date: 2024-02-26 name: PersonGen BioTherapeutics (Suzhou) Co., Ltd. class: INDUSTRY name: Seco... |
<|newrecord|> nctId: NCT06279013 id: NRG-CC012CD id: NCI-2023-10831 type: REGISTRY domain: CTRP (Clinical Trial Reporting Program) id: NRG-CC012CD type: OTHER domain: NRG Oncology id: NRG-CC012CD type: OTHER domain: DCP id: NRG-CC012CD type: OTHER domain: CTEP id: R01CA279472 type: NIH link: https://reporter.nih.gov/qu... |
<|newrecord|> nctId: NCT06279000 id: CTU 22/025 briefTitle: Colchicine in Patients at Cardiac Risk Undergoing Major Non-Cardiac Surgery acronym: COLCAT overallStatus: NOT_YET_RECRUITING date: 2024-10-01 date: 2027-09-30 date: 2028-09-30 date: 2024-02-26 date: 2024-02-28 name: Cantonal Hospital of St. Gallen class: OTHE... |
However, research in recent years has yielded limited preventive and therapeutic measures for PMI/MACE. Recent studies in patients with chronic and acute coronary artery disease have shown that colchicine administration can reduce the risk of cardiovascular events. |
These encouraging results in non-surgical patients ask for a similar investigation in patients undergoing major non-cardiac surgery. The aim of the proposed study is to investigate the effects of perioperative colchicine administration on the incidence of PMI/MACE. conditions: Cardiovascular Diseases conditions: Cardio... |
<|newrecord|> nctId: NCT06278987 id: ANES-2024-32661 briefTitle: Comparison of Cryoablation of Pericapsular Nerve Group (PENG) to Fascia Iliaca Catheter in Patients With a Hip Fracture overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2026-06-01 date: 2026-12-01 date: 2024-02-26 date: 2024-03-19 name: University... |
<|newrecord|> nctId: NCT06278974 id: PDSFGOCLMC-2023-001 briefTitle: Comparing Myopia Treatments in Youth: Defocus Spectacles, Glasses, and Ortho-K overallStatus: RECRUITING date: 2023-11-10 date: 2025-05-01 date: 2025-05-01 date: 2024-02-26 date: 2024-02-26 name: He Eye Hospital class: OTHER briefSummary: The research... |
<|newrecord|> nctId: NCT06278961 id: IRB 2021-4329 briefTitle: Families Filming Infants Learning Movement acronym: FILM overallStatus: RECRUITING date: 2021-01-28 date: 2024-09-30 date: 2024-09-30 date: 2024-02-26 date: 2024-02-26 name: Ann & Robert H Lurie Children's Hospital of Chicago class: OTHER name: Northwestern... |
<|newrecord|> nctId: NCT06278948 id: LRP23023-depigmenting cream briefTitle: Efficacy and Tolerability of Test Product Versus Cysteamine 5% in Treatment of Facial Epidermal Melasma overallStatus: RECRUITING date: 2023-10-06 date: 2024-06 date: 2024-06 date: 2024-02-26 date: 2024-02-26 name: Cosmetique Active Internatio... |
<|newrecord|> nctId: NCT06278935 id: APP-24-00887 briefTitle: Lifestyle Tailored Offloading for Diabetic Foot Ulcers overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2026-04 date: 2026-04 date: 2024-02-26 date: 2024-04-02 name: University of Southern California class: OTHER briefSummary: The goal of this pilot cli... |
<|newrecord|> nctId: NCT06278922 id: STUDY00001149 id: R01AA031010 type: NIH link: https://reporter.nih.gov/quickSearch/R01AA031010 briefTitle: Evaluating Signs of Safety: A Deaf-Accessible Therapy Toolkit for AUD and Trauma overallStatus: NOT_YET_RECRUITING date: 2024-09-30 date: 2028-09-30 date: 2028-09-30 date: 2024... |
<|newrecord|> nctId: NCT06278909 id: 6036699 briefTitle: Trigeminal Nerve Stimulation in Treatment-resistant Generalized Anxiety Disorder: a Feasibility Study overallStatus: RECRUITING date: 2024-01-18 date: 2025-01-30 date: 2025-06-30 date: 2024-02-26 date: 2024-03-26 name: Dr. Rafael Freire class: OTHER briefSummary:... |
* The primary objective is to ascertain if TNS is a safe and well-tolerated treatment for patients with TR-GAD. |
* The secondary objective will be to monitor changes in GAD symptom severity throughout the study. |
Results from this study will inform a randomized controlled trial to be conducted in the future. conditions: Generalized Anxiety Disorder studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: This is a traditional feasibility study, which evaluates preliminary... |
<|newrecord|> nctId: NCT06278896 id: 23-684-END briefTitle: Early Neutropenic Fever De-escalation of Antibiotics Study acronym: END overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2026-03-01 date: 2028-03-01 date: 2024-02-26 date: 2024-02-26 name: Brigham and Women's Hospital class: OTHER name: Dana-Farber Can... |
<|newrecord|> nctId: NCT06278883 id: Pro00115007 id: R01HG011794 type: NIH link: https://reporter.nih.gov/quickSearch/R01HG011794 briefTitle: Genomic Medicine Risk Assessment Care for Everyone - Implementation Phase acronym: GRACE overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-06-30 date: 2025-06-30 date: 2... |
Aim 1: Develop a scalable implementation framework that guides each unique clinical setting, including low resource settings, in deploying GRACE effectively for the needs of their patients and providers. |
Aim 2: Facilitate the potential for genomic medicine to promote population health by broadening access to and uptake of genomic risk assessment by the general population through a pragmatic implementation-effectiveness trial of GRACE. |
Aim 3: Reduce health disparities related to genomic medicine by allowing individual adaption of GRACE to suit their level of resources, education, and access within a pragmatic implementation-effectiveness trial. |
Three sets of participants will be engaged: patients (n=750), providers (n=25), and family members of "probands" (i.e., patients that have a genetic change that increases risk, n\~500). |
Patient participants will be asked to complete a baseline survey, enter their family health history information into MeTree (a family health history web-based platform) and complete a survey about their experience using the platform. Subsequent study procedures will depend on: 1) the results of their MeTree risk evalua... |
Provider participants will be providers who are the primary care physicians treating one or more patients enrolled in the patient participant group. Providers will be notified on a patient by patient basis once the patient participant under their care has complete the risk assessment process and the risk report is avai... |
Blood relatives of the probands who are identified by the proband as open to engaging with the study will be contacted and offered genetic counseling and genetic testing. conditions: Cardiovascular Diseases conditions: Cancer conditions: Liver Diseases conditions: Hyperthermia studyType: INTERVENTIONAL phases: NA alloc... |
<|newrecord|> nctId: NCT06278870 id: SYSKY-2023-431-02 briefTitle: Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial overallStatus: RECRUITING date: 2023-09-06 date: 2031-06-30 date: 2031-06-30 date: 2024-02-26 date: 2024-02-26 name: Sun Yat-Sen Memoria... |
* Analyse the efficacy and safety of disitamab vedotin in combination with pyrotinib versus the standard first-line treatment of THP. |
* Explore the impact of biomarkers on clinical efficacy and safety of the combination of disitamab vedotin in combination with pyrotinib treatment. |
Participants in the experimental group will receive disitamab vedotin in combination with pyrotinib for 6-8 cycles (each cycle lasting 28 days), followed by maintenance treatment with trastuzumab in combination with pyrotinib. Participants in the control group will receive paclitaxel in combination with trastuzumab and... |
Researchers will compare disitamab vedotin in combination with pyrotinib versus the standard first-line treatment of paclitaxel in combination with trastuzumab and pertuzumab to see if disitamab vedotin in combination with pyrotinib could be a new option for first-line treatment of HER2-positive metastatic breast cance... |
<|newrecord|> nctId: NCT06278857 id: QCGC-001/2023 briefTitle: SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr) acronym: SATELLITE overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2026-06-30 date: 2028-06-30 date: 2024-02-26 date: 2024-02-26 name: Queensland Cen... |
Participants will have seven dostarlimab sessions over 12 months. The treatment plan involves four cycles every three weeks, followed by a three-week break, and then three cycles every six weeks. |
This research is a promising step toward a new, less invasive treatment choice for patients with specific genetic traits. It expands the range of care options for endometrial cancer. conditions: Endometrial Cancer Stage I conditions: Mmr Deficiency conditions: Endometrioid Endometrial Adenocarcinoma conditions: Immune-... |
<|newrecord|> nctId: NCT06278844 id: 3020 briefTitle: Exercise Capacity Improvement by Conduction System Pacing in heArt Failure patieNts Without Compelling CRT inDication acronym: ESCPAND overallStatus: RECRUITING date: 2023-12-12 date: 2026-09 date: 2027-12 date: 2024-02-26 date: 2024-02-26 name: University Hospital,... |
<|newrecord|> nctId: NCT06278831 id: 2023-02645 briefTitle: Efficacy of Structured SOcial COnsultation and Support in Reducing the FINancial Burden of Radiotherapy acronym: SOCOFIN-1 overallStatus: RECRUITING date: 2023-07-08 date: 2024-05-31 date: 2024-10-15 date: 2024-02-26 date: 2024-02-26 name: University Medical C... |
* Assess the extent of financial burden of patients undergoing radiotherapy |
* Identify clinical and socio-economical factors correlated with the occurrence and extent of financial toxicity |
* Design a structured social consultation to reduce financial burden induced by radiotherapy |
Inclusion criteria: |
1. age ≥ 18 years of age |
2. indication for radiation treatment of a malignant disease |
3. Karnofsky Performance score (KPS) ≥ 70% |
4. Life expectancy ≥ 3 months |
Exclusion criteria: |
1. Inability to provide informed consent |
2. Inability to attend study visits and fulfill data collection requirements |
3. Simultaneous participation in other studies which could interfere with this study Primary outcome: Financial burden as expressed by the COST score, measured at baseline and 3 months after completion of radiotherapy |
Secondary outcomes: |
* Socio-Economic factors at baseline |
* Health-related quality of life (EORTC QLQ-C30) at baseline and 3 months |
* Depression (PHQ-9) at baseline and 3 months |
* Coping mechanisms to address financial burden |
Primary Endpoint: Influence of secondary outcomes on changes of the primary outcome (COST-Score) between baseline and 3 months. |
Secondary Endpoints: |
* Changes in the COST-Score over time |
* Changes in PHQ-9 over time |
* Changes in EORTC QLQ-C30 over time |
This is an exploratory pilot study. To assess the compliance and effectiveness of the used methods all patients willing to participate in the given time period will be enrolled. |
To be assessed for eligibility: n = 300 To be allocated/randomised (if applicable) to trial: n = 150 To be analysed: n = 120 conditions: Financial Toxicity studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 225 type: ESTIMATED name: Questionnaire measure: Financial Toxicity measure:... |
<|newrecord|> nctId: NCT06278818 id: MNESYS-PE0000006 briefTitle: Effects of Telerehabilitation on Brain Network Connectivity overallStatus: RECRUITING date: 2023-12-07 date: 2024-06-07 date: 2026-03-01 date: 2024-02-26 date: 2024-02-26 name: University of Pavia class: OTHER name: University of Parma name: University o... |
This longitudinal and multicenter study applies innovative cognitive telerehabilitation (TR) methods and evaluates their impact on functional parameters obtained with high-density electroencephalogram (HD-EEG) and resting-state functional magnetic resonance imaging (rsFMRI). The goal is to identify neurophysiological c... |
The study aims to: |
* Identify correlations between improvement in cognitive performance and functional brain data. |
* Use acquired knowledge to develop neurologically guided TR approaches for broader use. |
The research will include patients diagnosed with MCI associated with neurodegenerative diseases. Primary outcome measures include changes in resting-state brain connectivity assessed through HD-EEG and rsFMRI. Secondary outcomes involve the assessment of changes in neuropsychological measures, caregiver burden, immedi... |
The study is designed to last 30 months, with follow-up assessments at three time points. The primary outcomes will be evaluated using rsFMRI and HD-EEG instrumental acquisitions, the secondary outcomes will be evaluated using clinical assessments and neuropsychological tests. conditions: Mild Cognitive Impairment stud... |
<|newrecord|> nctId: NCT06278805 id: ayk22 briefTitle: Adaptation and Validation of the LUNS for Use in Turkey. overallStatus: RECRUITING date: 2024-03-01 date: 2024-12-01 date: 2025-02-01 date: 2024-02-26 date: 2024-04-11 name: Uşak University class: OTHER name: Ankara University name: Istanbul University briefSummary... |
Our hypothesis in this study is: |
- The Turkish Longer-term Unmet Needs after Stroke Questionnaire (T-LUNS) is a valid tool for assessing the unmet needs of stroke patients in the Turkish population. conditions: Stroke conditions: Disability Physical conditions: Quality of Life studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_... |
<|newrecord|> nctId: NCT06278792 id: Z-2021104 briefTitle: Readily Available Urinary Sodium Analysis in Patients With Acute Decompensated Heart Failure acronym: EASY-HF overallStatus: COMPLETED date: 2022-03-07 date: 2023-07-12 date: 2024-01-05 date: 2024-02-26 date: 2024-02-26 name: Ziekenhuis Oost-Limburg class: OTHE... |
* difference in natriuresis and diuresis |
* feasibility of the protocol. |
Participants will be asked to gather two 24 h urine collections. |
Researchers will compare SOC versus nurse-led diuretic titration to see if there is a difference in natriuresis after 48 hours. conditions: Acute Decompensated Heart Failure studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The EASY-HF study was a sing... |
<|newrecord|> nctId: NCT06278779 id: X23-0311 briefTitle: Comparative Effectiveness Study of Two Forms of Ketamine for Treatment-resistant Depression acronym: TREK overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2027-04 date: 2027-04 date: 2024-02-26 date: 2024-03-13 name: The George Institute class: OTHER name: ... |
* How the two formulations compare in terms of their effectiveness in treating TRD. |
* How the two formulations compare in their acceptability to patients, safety, effects on patient quality of life and function, and cost effectiveness. |
Participants will be randomised to receive either Spravato® or racemic ketamine treatment and asked to complete some questionnaires to assess the effects on mood, treatment acceptability, side effects, quality of life and function, and health economic outcomes. conditions: Treatment Resistant Depression studyType: INTE... |
<|newrecord|> nctId: NCT06278766 id: M24-416 briefTitle: A Study to Assess the Mass Balance of [14C] ABBV-552 in Healthy Male Participants Following Single Oral Dose Administration overallStatus: COMPLETED date: 2024-02-21 date: 2024-04-19 date: 2024-04-19 date: 2024-02-26 date: 2024-04-29 name: AbbVie class: INDUSTRY ... |
<|newrecord|> nctId: NCT06278753 id: 2025/05/02 briefTitle: Comparison of Standard Cystoscopy With Carbon Dioxide Cystoscopy overallStatus: RECRUITING date: 2021-07-01 date: 2024-03-01 date: 2024-04-01 date: 2024-02-26 date: 2024-02-26 name: Tepecik Training and Research Hospital class: OTHER briefSummary: For the eval... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.